The global bio-imaging market involves sophisticated imaging modalities that are used to obtain both anatomical and functional views and biochemical activities at cellular and molecular level in human and non-human forms. Some of the commonly used bio-imaging modalities are MRI, ultrasound, X-ray, optical imaging, microscopic CT, PET scan and single photon emission computed tomography (SPECT).

Advancements in Global Bio-imaging Market Size technologies helps in better understanding of biological processes, disease diagnosis and for improving therapeutic interventions. The bio-imaging modalities are increasingly being used for various stages of drug development including discovery, pre-clinical and clinical testing that enables longitudinal assessment of treatment response over time.

The Global bio-imaging market is estimated to be valued at US$ 5.74 Bn in 2024 and is expected to exhibit a CAGR of 15% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the global bio-imaging market are Bracco Imaging S.P.A, Bayer HealthCare Pharmaceuticals, Esaote S.p.A, Digirad Corporation, FONAR Corporation, GE Healthcare, Hologic Inc., Hitachi Medical Corporation, Lantheus Medical Imaging, Inc., Covidien Pharmaceuticals, Mindray Medical International Limited., Gamma Medica Inc., Samsung Medison Co., Ltd., and Philips Healthcare. These companies provide advanced bio-imaging modalities as well as offer clinical and application support services globally.

The demand for bio-imaging technologies is growing rapidly owing to increasing prevalence of chronic diseases like cancer and neurological disorders globally. Increasing applications of bio-imaging for drug research and clinical trials is further fueling the market growth. Advancements in bio-molecular imaging is enabling accurate disease diagnosis at molecular level which was previously not possible.

Get More Insights On Global Bio-imaging Market